Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization

被引:90
作者
Green, NS
Palaninathan, SK
Sacchettini, JC
Kelly, JW
机构
[1] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
[3] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA
关键词
D O I
10.1021/ja030294z
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The misfolding of transthyretin (TTR), including rate-limiting tetramer dissociation and partial monomer denaturation, is sufficient for TTR misassembly into amyloid and other abnormal quaternary structures associated with senile systemic amyloidosis, familial amyloid polyneuropathy, and familial amyloid cardiomyopathy. Monovalent small molecules that bind to one or both of the unoccupied thyroid hormone binding sites at the TTR quaternary structure interface stabilize the native state, raising the kinetic barrier for tetramer dissociation sufficiently that the rate of dissociation, and therefore amyloidosis, becomes slow. Bivalent amyloid inhibitors that bind to both binding sites simultaneously are reported herein. The candidate bivalent inhibitors are generally unable to bind to the native TTR tetramer and typically do not engage in monovalent binding owing to a strong inhibitor orientation preference. However, the TTR quaternary structure can assemble around several of the bivalent inhibitors if the inhibitor intercepts the protein before assembly occurs. Some of the wild-type TTR-bivalent inhibitor complexes prepared in this fashion retain a tetrameric structure when subjected to substantial denaturation stresses (8 M urea, 120 h). The best bivalent inhibitor reduced acid-mediated TTR (3.6 muM) amyloid fibril formation to 6% of that exhibited by TTR in the absence of inhibitor, a significant improvement over the similar to30% observed for the best monovalent inhibitors (3.6 muM, 72 h). The apparent dissociation rate of the best bivalent inhibitor is effectively zero, consistent with the idea that TTR tetramer dissociation and inhibitor dissociation are linked-as a result of the inhibitor-templating tetramer assembly. X-ray cocrystal structures of two of the complexes demonstrate that the bivalent inhibitors simultaneously occupy both sites in TTR, consistent with the 1:1 binding stoichiometry derived from HPLC analysis. The purpose of this study was to demonstrate that bivalent inhibitors could be useful; what resulted are the best inhibitors produced to date. In this context, molecules capable of intercepting TTR during folding and assembly in the lumen of the endoplasmic reticulum would be of obvious interest.
引用
收藏
页码:13404 / 13414
页数:11
相关论文
共 45 条
  • [31] Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors
    Oza, VB
    Smith, C
    Raman, P
    Koepf, EK
    Lashuel, HA
    Petrassi, HM
    Chiang, KP
    Powers, ET
    Sachettinni, J
    Kelly, JW
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (02) : 321 - 332
  • [32] Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase - Steps toward novel drugs for treating Alzheimer's disease
    Pang, YP
    Quiram, P
    Jelacic, T
    Hong, F
    Brimijoin, S
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (39) : 23646 - 23649
  • [33] Inhibiting transthyretin conformational changes that lead to amyloid fibril formation
    Peterson, SA
    Klabunde, T
    Lashuel, HA
    Purkey, H
    Sacchettini, JC
    Kelly, JW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) : 12956 - 12960
  • [34] Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors
    Petrassi, HM
    Klabunde, T
    Sacchettini, J
    Kelly, JW
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2000, 122 (10) : 2178 - 2192
  • [35] Transthyretin related familial amyloid polyneuropathy
    Planté-Bordeneuve, V
    Said, G
    [J]. CURRENT OPINION IN NEUROLOGY, 2000, 13 (05) : 569 - 573
  • [36] Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma
    Purkey, HE
    Dorrell, MI
    Kelly, JW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (10) : 5566 - 5571
  • [37] Benzoxazoles as transthyretin amyloid fibril inhibitors: Synthesis, evaluation, and mechanism of action
    Razavi, H
    Palaninathan, SK
    Powers, ET
    Wiseman, RL
    Purkey, HE
    Mohamedmohaideen, NN
    Deechongkit, S
    Chiang, KP
    Dendle, MTA
    Sacchettini, JC
    Kelly, JW
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (24) : 2758 - 2761
  • [38] REID DG, 1989, J BIOL CHEM, V264, P2013
  • [39] Therapeutic strategies for human amyloid diseases
    Sacchettini, JC
    Kelly, JW
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) : 267 - 275
  • [40] BIOCHEMICAL MARKER IN FAMILIAL AMYLOIDOTIC POLYNEUROPATHY, PORTUGUESE TYPE - FAMILY STUDIES ON THE TRANSTHYRETIN (PREALBUMIN)-METHIONINE-30 VARIANT
    SARAIVA, MJM
    COSTA, PP
    GOODMAN, DS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (06) : 2171 - 2177